59° Rain

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Community Choice

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Optimi Health Corp (OP:OPTHF)

0.2382 +0.0048 (+2.06%)

Streaming Delayed Price Updated: 1:31 PM EDT, May 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Optimi Health Corp

< Previous 1 2 3 Next >

PsychedelicNewsBreaks – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) Launches Ibogaine Initiative Amid U.S. Policy Shift

April 21, 2026

Via Investor Brand Network

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026

(April 20, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic

Via PressReach

Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering

March 16, 2026

Vancouver, British Columbia-March 16, 2026 - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE:8BN) (the "Company" or "Optimi"), a commercial-stage

Via PressReach

Topics Regulatory Compliance

Optimi Health Completes MD-MA Export for PTSD Treatment Under Australia’s Authorised Prescriber Scheme

February 09, 2026

(February 9, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychoactive

Via PressReach

Optimi Health Completes First 2026 Production of MD-MA and Psilo Capsules

January 26, 2026

(January 26, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug

Via PressReach

Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition ↗

September 16, 2024

Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pipeline with key acquisitions and partnerships.

Via Benzinga

New Milestone In Psychedelics Market: Canadian Start-Up Will Export Psilocybin And MDMA To Australia ↗

June 05, 2024

Canada Magic Mushrooms and MDMA market is hitting new milestones as canada has licensed Optimi to export psilocybin and MDMA to Australia

Via Benzinga

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗

April 17, 2024

Via Benzinga

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

Optimi To Supply Psilocybin For New Zealand's Mātai Medical Research Institute ↗

April 09, 2024

Via Benzinga

Two Top Biotechs Forge MDMA Supply Deals For Clinical Research ↗

March 26, 2024

Via Benzinga

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review ↗

March 16, 2024

Via Benzinga

Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More ↗

March 01, 2024

Via Benzinga

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗

January 26, 2024

Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.

Via Benzinga

Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More ↗

January 08, 2024

Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.

Via Benzinga

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

Optimi Health Will Supply Psychedelics To Canada's SAP, Secures CA$1M Private Financing ↗

September 08, 2023

Health Canada has approved an amendment to Optimi Health’s (OTCQX: OPTHF) dealer's license, effectively allowing the company to supply MDMA and psilocybin drugs to the country’s Special Access Program...

Via Benzinga

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

Natural Psilocybin Companies Diversify: Latest By Optimi, Red Light Holland And A European Player ↗

August 01, 2023

Optimi Completes Novel Extraction Process and Files U.S. Prov. Patent

Via Benzinga

MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University ↗

June 20, 2023

Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice...

Via Benzinga

Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More ↗

May 23, 2023

Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...

Via Benzinga

The Psychedelic Mushrooms Market; Between Legitimate Harvesting And Illegal Retail Sales ↗

May 17, 2023

While psychedelics reform is clearly gaining momentum, not only in the U.S. but notably in places like Australia and less so Canada. The fact is, all compounds remain currently Schedule I drugs (or...

Via Benzinga

Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More ↗

May 15, 2023

Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...

Via Benzinga

Optimi Health Boosts Psilocybin Production With New Health Canada License And Supply Deal ↗

May 11, 2023

Psychedelics research and manufacturing company Optimi Health Corp. (OTCQX: OPTHF) received a “Natural Health Product Site" license, adding to its existing permits to produce and supply psychedelic...

Via Benzinga

What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry ↗

April 03, 2023

The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey.

Via Benzinga

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗

March 07, 2023

Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...

Via Benzinga

Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla ↗

March 06, 2023

The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia.

Via Benzinga

Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California ↗

March 02, 2023

Optimi Health Enters Australian Medical Psychedelics Market Via Mind Medicine Australia

Via Benzinga

Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More ↗

February 13, 2023

Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More

Via Benzinga

How Do Psilocybin And MDMA Work Together? This Proposed Experiential Study Is Set To Find Out ↗

February 09, 2023

Licensed psychedelic drugs producer Optimi Health Corp. (OTCQX: OPTHF) submitted a Health Canada clinical trial application (CTA) for a Phase 1 study that will assess the safety of combining its...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Optimi Health Corp (OP:OPTHF)

All News about Optimi Health Corp

Sections

Services